Schedule a COVID vaccine or booster appointment:
Log in to myPennMedicine or call us 8am to 5pm, Monday through Friday, at 267-758-4902.
Sees patients age 18 and up
Sees patients age 18 and up
Recognized by America's Top Doctors, 2007, 2008, 2010 - 2020
Recognized by Best Doctors in America, 2009 - 2020
Recognized in Philadelphia magazine's annual Top Docs issues, 2004 - 2021
Perelman Center for Advanced Medicine
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown above from our internal platform, PMX Feedback. Responses are measured on a scale of 1 to 5 with 5 being the best score. Scores reflect either the most recent 12 months of surveys or the most recent 30 surveys overall. Data is updated monthly and comments remain on the profile for 12 months.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Patients that are treated in outpatient or hospital environments may receive different surveys.
Porter DL, Levine BL, Kalos M, Bagg A, June CH: Delayed tumor lysis and CLL remission from chimeric antigen receptor modified T cells New England Journal of Medicine 365 : 725-733,2011.
Reshef R, Luger S, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL.: Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease New England Journal of Medicine 367 : 135-145,2012.
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH.: T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia Science Translational Medicine 3 : 95ra73,2011.
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL.: Peripheral blood stem cells versus bone marrow from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network protocol 0201, a phase III, prospective, randomized trial. New England Journal of Medicine 367 : 1487-1496,2012.
Porter DL, Alyea EP, Antin JH, DeLima M, Estey, E, Falkenburg JHF, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K.: NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood and Marrow Transplant 16 : 1467-1503,2010.
Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL.: High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allogeneic SCT. Bone Marrow Transplant 47 : 1332-1337 ,2011.
Rager A, Frey N, Goldstein SC, Reshef R, Hexner EO, Loren A, Luger SM, Perl, A, Tsai D, Davis J, Vozniak M, Smith J, Stadtmauer EA, Porter DL.: Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease Bone Marrow Transplantation epub : 2010.
Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL.: Allogeneic hematopoietic stem cell transplantation for primary cutaneous T cell lymphomas Bone Marrow Transplantation 47 : 940-945,2012.
Rager A, Porter DL: Cellular therapy following allogeneic stem cell transplantation Therapeutic Advances in Hematology 2 (6): 416 - 435.,2011.
Goldstein SC, Porter DL: Allogeneic immunotherapy to optimize the graft-versus tumor effect: concepts and controversies. Expert Review of Hematology 3 (3): 301-314,2010.
Porter DL, Hexner EO, Cooley S, Miller JS: Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation : 2008.
Goldstein S, Stein S, Porter DL: Treatment of Acute Graft vs Host Disease Allogeneic Stem Cell Transplantation. Clinical Research and Practice 2 : 747-765,2010.
Loren AW, Porter DL: Donor Leukocyte Infusions for the Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation
Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplantation 41 : 483,2007.
Porter, DL: RIC for MDS: The Glass is Half Full (commentary). , Blood 108 : 780-781,2006.
Porter DL, Antin JH: Donor Leukocyte Infusions in Myeloid Malignancies: New Strategies. Best Practice and Research: Clinical Hematology 19 (4): 737-756,2006.
Porter DL, Stadtmauer EA, Lazarus H.: "GVHD": Graft-vs-Host Disease or Graft-vs-Hodgkin's Disease? An Old Acronym with New Meaning. Bone Marrow Transplant 31 : 739-746,2003.
Loren AW, Luger SM, Duffy KM, Stadtmauer E, Tsai D, Schuster S, Nasta S, Klumpp T, Orloff G, Porter D.: Alemtuzumab prevents acute graft-vs-host disease (aGVHD) in non-myeloablative stem cell transplants (NST) from unrelated donors. Proc Am Soc Clin Oncol : 2003.
Hematology-OncologyPerelman Center for Advanced Medicine 12th Floor, South PavilionOffice #12-1503400 Civic Center Blvd
Patient appointments: 800-789-7366